



RepliCel™

Using Cells for Healing


OTCQB: REPCF | TSXV: RP | FRA:P6P2

COMPANY PROFILE Q2 2017

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics, one game-changing delivery platform



RCT-01
Tendon Repair
Active Licensing
Discussions are Currently Underway

PHASE 1/2A CLINICAL TRIAL
Randomized (3:1) double-blind, placebo-controlled trial at UBC Sports Medicine Clinic (10 participants)
Primary Endpoint: Safety and Tolerance
Secondary Endpoint: Efficacy at 6 months
Results: Data confirms product safety and clinical potential for tendon regeneration and healing including an overall 15.3% improvement in total score compared to baseline, and a nearly 100% recovery in function (by VISA-A scoring) in two patients.

RCS-01
Dermal Rejuvenation
Active Licensing
Discussions are Currently Underway

PHASE 1 CLINICAL TRIAL
Phase 1 randomized, double-blinded, placebo-controlled trial at IUF Leibniz-Institut für umweltmedizinische Forschung (Germany)
Primary Endpoint: Safety & Tolerance
Secondary Endpoint: Efficacy at 6, 12 months
Results: RCS-01 is very safe and has the potential to reverse effects of aging skin.

RCH-01
Pattern Baldness
Strong ongoing interest by several parties including multinational companies in the aesthetic industry, including Shiseido (Japan)

PHASE 2 CLINICAL STUDY
Japan (ongoing) Potential Market Launch. Costs covered by Shiseido, Data expected 2018. Potential near-term market launch.
Germany (pending) Dosing & treatment frequency trial
Clinical trial application in preparation for dosing frequency.
Primary Endpoint: Hair Density
Study results from recent, first-in-human, five-year clinical trial firmly establish product safety and confirm ongoing clinical and product development strategy.

RCI-02 PATENTED DERMAL INJECTION DEVICE

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch



Poised for growth and momentum



Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercialization And Revenue

Patented injection device could generate sales and revenues as early as 2018 in Europe, and then in the U.S.

Highly Favourable Results from all three Clinical Trials

Three biologic products in Phase I and II human clinical trials all demonstrated highly-favourable results, and are attracting interest from other potential licencing partners; first could reach the Japanese market in 2018.

Management Is Commercially-Focused And Strategic

Aggressively pursuing licensing and co-development deals over the next 24 months.

Capital Structure (as at Feb 2, 2017)

Current market cap. (approx.)	~\$25M
Total money raised through equity to-date	~\$25M
Total revenue to-date (including initial Shiseido licensing payment)	\$3.8M
Current Monthly Burn Rate	~\$180,000
Shares Issued and Outstanding (Basic/FD) (post-consolidation completed in Aug 2016)	18.3M 32.8 Diluted

Board and Management Team

David Hall
Chairman

Geoff MacKay, BSc
Director

Peter Lewis, CA
Director

Dr. John Challis, PhD
Director

Hugh Rogers, BSc, LLB
Director

R. Lee Buckler, B. Ed, LLB
President, CEO & Director

Dr. Rolf Hoffman, MD
Chief Medical Officer

Dr. Kevin McElwee, PhD
Chief Scientific Officer

Tom Kordyback, CA
Chief Financial Officer

Darrell Panich, MSc, PMP, CPM
Clinical Consultant

RepliCel Life Sciences

Suite 900, 570 Granville Street
Vancouver, BC V6C 3P1
604-248-8730

www.replicel.com